Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study

Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study

Summary: Background: Hepatitis C virus (HCV) infection is increasing among pregnant women because of the opioid epidemic, yet there are no interventions to reduce perinatal HCV transmission or to treat HCV during pregnancy. Physiological changes in pregnancy alter the pharmacokinetics of some medic...

Full description

Bibliographic Details
Main Authors: Catherine A Chappell, MD, Kimberly K Scarsi, PharmD, Brian J Kirby, PhD, Vithika Suri, MSc, Anuj Gaggar, MD, Debra L Bogen, ProfMD, Ingrid S Macio, PA, Leslie A Meyn, PhD, Katherine E Bunge, MD, Elizabeth E Krans, MD, Sharon L Hillier, ProfPhD
Format: Article
Language:English
Published: Elsevier 2020-09-01
Series:The Lancet Microbe
Online Access:http://www.sciencedirect.com/science/article/pii/S2666524720300628

Internet

http://www.sciencedirect.com/science/article/pii/S2666524720300628

Similar Items